¿ Celtrix Pharmaceuticals Inc., of San Jose, Calif., said final Phase IIa data on SomatoKine in patients with Type I diabetes showed it decreased average daily insulin requirements by 49 percent and reduced average daily blood glucose by 23 percent from the levels attained by conventional insulin therapy. The data were presented at two recent scientific meetings.
¿ Gensia Sicor Inc., of Irvine, Calif., changed its name to Sicor Inc. It is listed on the Nasdaq exchange as SCRI.
¿ Gliatech Inc., of Cleveland, presented data showing its monoclonal antibody, GT4086, effectively blocked complement activation in models of cardiopulmonary bypass and tissue injury. The company is developing a humanized antibody that will undergo preclinical testing.
¿ Hyseq Inc., of Sunnyvale, Calif., said its analysis of more than 1 million genes in a collaboration with Kirin Brewery Co. Ltd., of Tokyo, yielded 51 genes associated consistently with cell growth factor activity. In the second phase of the collaboration the companies will use those genes to identify lead product candidates.
¿ MediChem Research Inc., of Lemont, Ill., which does chemistry work for pharmaceutical and biotechnology companies, raised $35 million in a private placement. The financing was led by MedEquity Investors LLC and Chase Capital Partners.
¿ Organogenesis Inc.'s Apligraf, in preliminary data from a 22-patient study, helped fully heal diabetic foot ulcer wounds in eight of 10 people compared to five of 12 who were treated with standard care. The Canton, Mass., company's product is marketed in the U.S. by Novartis Pharmaceuticals Inc., of East Andover, N.J.